ArticlePloS one2012
The effect of miR-338-3p on HBx deletion-mutant (HBx-d382) mediated liver-cell proliferation through CyclinD1 regulation.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- microRNA-338-3p suppresses lipopolysaccharide-induced inflammatory response in HK-2 cells.BMC molecular and cell biology · 2022Article
- Implications of SARS-CoV-2 Mutations for Genomic RNA Structure and Host microRNA Targeting.International journal of molecular sciences · 2020Article
- Microarray expression and functional analysis of circular RNAs in the glomeruli of NZB/W F1 mice with lupus nephritis.Experimental and therapeutic medicine · 2019Article
- LncRNA ABHD11-AS1 promotes the development of endometrial carcinoma by targeting cyclin D1.Journal of cellular and molecular medicine · 2018Article
- Molecular mechanism of estrogen-mediated neuroprotection in the relief of brain ischemic injury.BMC genetics · 2018Article
- MicroRNA-338-3p targets SOX4 and inhibits cell proliferation and invasion of renal cell carcinoma.Experimental and therapeutic medicine · 2017Article
- Suberoylanilide hydroxamic acid sensitizes neuroblastoma to paclitaxel by inhibiting thioredoxin-related protein 14-mediated autophagy.Cancer science · 2017Article
- MiR-338-3p inhibits the growth and invasion of non-small cell lung cancer cells by targeting IRS2.American journal of cancer research · 2017Article
- Anticancer bioactive peptide-3 inhibits human gastric cancer growth by targeting miR-338-5p.Cell & bioscience · 2016Article
- MicroRNA-338-3p suppresses metastasis of lung cancer cells by targeting the EMT regulator Sox4.American journal of cancer research · 2016Review
- MiR-338-3p targets pyruvate kinase M2 and affects cell proliferation and metabolism of ovarian cancer.American journal of translational research · 2016Article
- Article
- Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma.World journal of gastroenterology · 2014Review
- miRNAs affect the development of hepatocellular carcinoma via dysregulation of their biogenesis and expression.Cell communication and signaling : CCS · 2014Review
- Multi-gene fluorescence in situ hybridization to detect cell cycle gene copy number aberrations in young breast cancer patients.Cell cycle (Georgetown, Tex.) · 2014Article
- Regulation of viral oncogenesis by microRNAs.Molecular & cellular oncology · 2014Review
- Vitamin C mitigates oxidative stress and tumor necrosis factor-alpha in severe community-acquired pneumonia and LPS-induced macrophages.Mediators of inflammation · 2014Article
- Epigenetic silencing of miR-338-3p contributes to tumorigenicity in gastric cancer by targeting SSX2IP.PloS one · 2013Article
- Hepatitis B Virus-Encoded X Protein Downregulates EGFR Expression via Inducing MicroRNA-7 in Hepatocellular Carcinoma Cells.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- CD133/prominin-1-mediated autophagy and glucose uptake beneficial for hepatoma cell survival.PloS one · 2013Article
Corrections and comments
- Retraction · 2013-03-08Duplication of Data · Duplication of/in Image · Investigation by Company/Institution · Investigation by Journal/Publisher · Manipulation of Images ·
- Retracted
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHepatitis B Virus (HBV) DNA integration and HBV X (HBx) deletion mutation occurs in HBV-positive liver cancer patients, and C-terminal deletion in HBx gene mutants are highly associated with hepatocarcinogenesis. Our previous study found that the HBx-d382 deletion mutant (deleted at nt 382-400) can down-regulate miR-338-3p expression in HBx-expressing cells. The aim of the present study is to examine the role of miR-338-3p in the HBx-d382-mediated liver-cell proliferation.
methodsWe established HBx-expressing LO2 cells by Lipofectamine 2000 transfection. A miR-338-3p mimics or inhibitor was transfected into LO2/HBx-d382 and LO2/HBx cells using miR-NC as a control miRNA. In silico analysis of potential miR-338-3p targets revealed that miR-338-3p could target the cell cycle regulatory protein CyclinD1. To confirm that CyclinD1 is negatively regulated by miR-338-3p, we constructed luciferase reporters with wild-type and mutated CyclinD1-3'UTR target sites for miR-338-3p binding. We examined the CyclinD1 expression by real-time PCR and western blot, and proliferation activity by flow cytometric cell cycle analysis, Edu incorporation, and soft agar colony.
resultsHBx-d382 exhibited enhanced proliferation and CyclinD1 expression in LO2 cells. miR-338-3p expression inhibited cell proliferation in LO2/HBx-d382 cells (and LO2/HBx cells), and also negatively regulated CyclinD1 protein expression. Of the two putative miR-338-3p binding sites in the CyclinD1-3'UTR region, the effect of miR-338-3p on the second binding site (nt 2397-2403) was required for the inhibition.
conclusionmiR-338-3p can directly regulate CyclinD1 expression through binding to the CyclinD1-3'UTR region, mainly at nt 2397-2403. Down-regulation of miR-338-3p expression is required for liver cell proliferation in both LO2/HBx and LO2/HBx-d382 mutant cells, although the effect is more pronounced in LO2/HBx-d382 cells. Our study elucidated a novel mechanism, from a new miRNA-regulation perspective, underlying the propensity of HBx deletion mutants to induce hepatocarcinogenesis at a faster rate than HBx.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.